Why fund managers see strategic value building in PharmX Technologies
PharmX Technologies now has both Chemist Warehouse and the Apotex Group's Dennis Bastas as strategic, board-represented shareholders, alongside new Marketplace and Stockview products.
31 Mar 2026 · 3 min read
In short
PharmX Technologies operates a mission-critical pharmaceutical ordering gateway through which most pharmacy purchasing dollars flow, according to QVG Capital.
Chemist Warehouse took a 10% stake in PharmX in February 2026, with an option to increase to 19.9%, and has placed a director on the PharmX board.
The company has also launched a Marketplace platform and a Stockview product giving pharmacies industry-wide stock level insights, seen as new monetisation opportunities.
Pharmaceutical ordering platform PharmX Technologies has attracted two strategic pharmacy sector investors onto its share register within the space of a few months. Naos Asset Management's March 2026 Monthly Report detailed a Chemist Warehouse director joining the PharmX board, following a February 2026 deal in which Chemist Warehouse took a 10% stake in the business with an option to increase to 19.9%, alongside a renewed and potentially expanded commercial relationship.
A mission-critical gateway with two strategic shareholders
QVG Capital's January 2026 Monthly Report described the core appeal of the business: most dollars spent within pharmacies flow through a gateway controlled by PharmX, with a stated strategy to expand into a marketplace model representing a high-margin growth opportunity, the first parts of which are already showing through the launch of a new marketplace and stock portal. Naos Asset Management's February 2026 Presentation added that PharmX had also launched Stockview, a product giving pharmacies better insight into industry-wide stock levels, alongside the Marketplace platform enabling improved order flow and monetisation.
There are two very strategic investors on the PharmX register and also on the board at the moment.
— Naos Asset Management, Monthly Report, March 2026
What managers are watching next
Naos Asset Management's March 2026 report noted the register now also includes a director from entities associated with Dennis Bastas and the Apotex Group, a second substantial shareholder alongside Chemist Warehouse, giving PharmX two strategic partners with direct board representation and a shared incentive in the platform's success. With the Marketplace and Stockview products both recently launched, QVG Capital's stated next catalyst is first-half results and evidence of customer adoption rates for the new offerings.
Questions
What is PharmX Technologies' core business?
PharmX Technologies operates a mission-critical pharmaceutical ordering gateway through which most dollars spent within pharmacies flow, and is expanding into a marketplace model to capture additional high-margin revenue.
Why did Chemist Warehouse invest in PharmX Technologies?
Chemist Warehouse took a 10% stake in PharmX Technologies in February 2026, with an option to increase to 19.9%, renewing and potentially expanding its existing commercial relationship with the company, and has since placed a director on the PharmX board.
What new products has PharmX Technologies launched?
PharmX Technologies has launched a new Marketplace platform enabling improved order flow and monetisation, and Stockview, a product giving pharmacies better insight into industry-wide stock levels.
3 managers, 7 comments, with each manager's latest recorded position.
See PHX